High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma - Wikidata - wikimedia - TriplyDB

High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma

High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma

http://www.wikidata.org/entity/Q34572289

about

Clinical, genetic, and immunohistochemical characterization of 70 Ukrainian adult cases with post-Chornobyl papillary thyroid carcinoma Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions Progress in molecular-based management of differentiated thyroid cancer Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer Genetic and epigenetic alterations in differentiated thyroid carcinoma.Applying new clinicopathological characteristics to prognostication in advanced thyroid carcinoma.Prognostic utility of BRAF mutation in papillary thyroid cancer.New insights in risk stratification of differentiated thyroid cancer.Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo Molecular pathogenesis and mechanisms of thyroid cancer BRAF mutation correlates with recurrent papillary thyroid carcinoma in Chinese patients BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer Development and characterization of six new human papillary thyroid carcinoma cell lines.Diagnosis and treatment of patients with thyroid cancer.Clinical and molecular features of papillary thyroid cancer in adolescents and young adults Association of TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC.Contactin 1 as a potential biomarker promotes cell proliferation and invasion in thyroid cancer B-Raf mutation and papillary thyroid carcinoma patients.Identification of Differentially Expressed Kinase and Screening Potential Anticancer Drugs in Papillary Thyroid Carcinoma.Xenograft models of head and neck cancers.Sorafenib in metastatic radioactive iodine-refractory differentiated thyroid cancer: A pilot study.Diagnostic markers and prognostic factors in thyroid cancer.Iodine mediated mechanisms and thyroid carcinoma.Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.mTOR Inhibition promotes TTF1-dependent redifferentiation and restores iodine uptake in thyroid carcinoma cell lines.Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer.Personalization of targeted therapy in advanced thyroid cancer.Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.Emerging role of multikinase inhibitors for refractory thyroid cancer.BRAFV600E mutation and papillary thyroid cancer: chicken or egg?Integrating Molecular Testing in the Diagnosis and Management of Children with Thyroid Lesions.Correlation between polymorphisms of BRAF gene and papillary thyroid carcinoma.Diagnostic significance of CK19, galectin-3, CD56, TPO and Ki67 expression and BRAF mutation in papillary thyroid carcinoma.The Transcription Factor ETV5 Mediates BRAFV600E-Induced Proliferation and TWIST1 Expression in Papillary Thyroid Cancer Cells Screening of pharmacogenetic variants associated with drug sensitivity in patients with papillary thyroid carcinoma using next generation sequencing BRAF V600E and RET/PTC Promote the Activity of Nuclear Factor-κB, Inflammatory Mediators, and Lymph Node Metastasis in Papillary Thyroid Carcinoma: A Study of 50 Patients in Inner Mongolia

P2860

Q24616408-13CE4B45-473A-42C6-B725-88F7A95EB79A Q26863326-AF856327-C975-4C16-A92A-2E6050503464 Q26999887-AA954AA4-C62E-4233-8DDC-282B46A1ACD0 Q27852780-848B802A-F595-447E-8B56-B22D87C9F33A Q30367068-719317A0-AF2C-4062-A196-9EA01DE3F5B0 Q33665984-3C7FCE38-FB2B-47CF-B141-FB2091C27668 Q33687963-382234E5-962A-4D48-ADC9-1AC07D898B66 Q33771120-52DF9B4F-BEB4-48B2-965B-AD31C81D6FB6 Q33915384-98AC0184-8477-4DA0-AFC0-911F8838A415 Q33931450-2CFF241F-A498-4E4F-90B9-B92E87C8A01B Q34109756-33457A49-E4CE-4AB1-A90E-59C589050C1E Q34329018-E4E9B1D2-F3F1-4BBC-A9C5-9A046BF1766B Q34637861-B0197489-CA9C-40F6-86F2-2FBB62CF608D Q34919430-F345CCEC-122E-47D4-A76E-D5ACEB7CBF69 Q35055107-F54DBE46-35E6-4A82-8C87-B83837D9B0AB Q35555583-805A9102-BC66-4271-BA97-19DD46165BCB Q36293091-648E5661-124C-429D-81AA-CC8457C62DDC Q36339926-EE372E80-B0A6-4B85-9329-C5AA25F4ACC9 Q36375125-EDE49E91-6865-42C7-9116-1A2FA79E65F6 Q36741221-56AFF2DA-6BC7-4F89-8EE0-9EAC9BEB5270 Q37293444-F3425364-7EF9-40FC-8A3A-FDF2FA515E9C Q37332682-65C50D1D-72A0-45A1-B63E-53288F832E5F Q37562646-F61818DD-380F-4FFE-BBDD-D88A16AF9E61 Q37620399-47C5B615-E5FF-4B0F-9DB7-AEEADF3C64D9 Q37643737-2532BEFA-0B8B-4136-BD10-9A67A813C14D Q37667684-11560516-488A-4245-A457-69854A15FA70 Q37767709-7931F632-2915-4DF2-8D07-5D0CA6A60111 Q38823954-64114211-32F2-4E9C-8F86-2687CF8E1F03 Q39006509-E12269B8-7C4B-4EF5-9438-C306EF8FD6AD Q39040663-98D10FD2-C0D2-4B45-94F8-C1531716F7A1 Q40922523-02043ADE-6CDF-4E9D-AD9C-96BE9706A4E5 Q41418283-F917EB54-8D6E-42D5-8BA1-4F859AF592A0 Q41837594-366FA454-7C4C-4774-A38A-A02331C5548A Q42707282-44944119-7208-4BE1-899F-3AD22ECC5B83 Q53352497-49AC5F71-3E2B-416F-AC5D-55DD4D2376B5 Q54164764-005E0B44-8337-4614-B9C9-3138B1FE055A Q54967888-D5A73CD8-4436-4446-B228-9EAB01B9F39D Q57150715-26805006-1B67-4B94-A1F8-BE07416FC593 Q58050534-D6AA2000-3CB0-4471-95CA-38A90FA92F3C Q58693775-AA40CB57-7E4B-4BAA-8B96-1845280F7753

P2860

High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma

http://www.wikidata.org/entity/Q34572289

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

High rate of BRAF and RET/PTC ...... nt papillary thyroid carcinoma

@ast

High rate of BRAF and RET/PTC ...... nt papillary thyroid carcinoma

@en

High rate of BRAF and RET/PTC ...... nt papillary thyroid carcinoma

@nl

type

label

High rate of BRAF and RET/PTC ...... nt papillary thyroid carcinoma

@ast

High rate of BRAF and RET/PTC ...... nt papillary thyroid carcinoma

@en

High rate of BRAF and RET/PTC ...... nt papillary thyroid carcinoma

@nl

prefLabel

High rate of BRAF and RET/PTC ...... nt papillary thyroid carcinoma

@ast

High rate of BRAF and RET/PTC ...... nt papillary thyroid carcinoma

@en

High rate of BRAF and RET/PTC ...... nt papillary thyroid carcinoma

@nl

P1433

Q34572289-626443E1-3C4C-4C34-B1D7-1DB9F7142278

P1476

Q34572289-72C58AEE-5384-45A6-847C-A840C240980E

P2093

Q34572289-2886AD79-9A88-4459-AB77-ED141492045D

Q34572289-476672F5-706D-413E-8400-AB29CB8AFC90

Q34572289-628712C8-0CDD-4BD8-B31D-855EA078D0FF

Q34572289-8569333B-0D58-4979-B460-7591C7B78C5A

Q34572289-9EA980C9-FC1C-4FC0-BB9A-6BCEC5822630

Q34572289-F0B7E52A-7A31-4894-ABF2-CC3404026431

P2860

Q34572289-061DEC30-FF33-4C41-9189-A34AE153B3C2

Q34572289-0715B5BB-B524-49E0-9800-1E9CA74D03AF

Q34572289-0A5E92D2-F2C2-44C4-855E-7EF66BFE5FCE

Q34572289-0CEBA0B8-1ABC-46B2-8C87-125B9D3E3226

Q34572289-0E363828-D46A-45B1-846A-D6E1702EAD94

Q34572289-18990490-A8AD-4B3F-B519-6EE19A23FBF8

Q34572289-1DAEA69B-2526-4CEE-8D8C-6536E14FB6D5

Q34572289-1DEECC8A-2D51-4F46-BFD4-4561BC537E0F

Q34572289-2286A9DC-CD12-417B-B34D-C62EC63F0D87

Q34572289-2A23342A-37CD-4BB7-8899-23911564EC5A

P304

Q34572289-911E69A8-69F8-43D0-AB3B-B837218580C5

P31

Q34572289-1B22E863-02A9-4F23-A912-24B3FC87CE7D

P356

Q34572289-72047A2C-6529-4F99-9A7A-DA994A827112

P407

Q34572289-981D192D-9CB1-4262-96BD-1F3BDFCFD500

P433

Q34572289-933DE7FB-5AF0-489D-BE3E-4ED3C9FAB94C

P478

Q34572289-FA78C2B5-DE9F-4FF7-9DF1-2838F6CBA403

P50

Q34572289-1293545B-0557-4B44-A87C-F2B555959509

P577

Q34572289-B5694115-0129-4E96-9B11-A3B78C41E171

P698

Q34572289-FF87CDA8-7969-4563-84C7-30B4A2655E02

P932

Q34572289-F0F3C6EC-51CA-43D8-AB33-9FD592268912

P356

1078-0432.CCR-08-0933

P1433

Clinical Cancer Research

P1476

High rate of BRAF and RET/PTC ...... nt papillary thyroid carcinoma

@en

P2093

Adel K El-Naggar

http://www.w3.org/2001/XMLSchema#string

Gary L Clayman

http://www.w3.org/2001/XMLSchema#string

Kathleen M Cieply

http://www.w3.org/2001/XMLSchema#string

Mitchell J Fredrick

http://www.w3.org/2001/XMLSchema#string

Thomas D Shellenberger

http://www.w3.org/2001/XMLSchema#string

Ying C Henderson

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A

Mutations of the BRAF gene in human cancer

Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers

BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas

RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis

The RAF proteins take centre stage

Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma.

The RET proto-oncogene in human cancers.

Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma.

PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas.

P304

485-491

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-08-0933

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Michelle D Williams

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19147753

http://www.w3.org/2001/XMLSchema#string

P932

3038608

http://www.w3.org/2001/XMLSchema#string